Physical and functional well-being and symptoms of ovarian cancer in women undergoing first-line of chemotherapy: a one-year follow-up-Reference-Cited by-同舟云学术

Physical and functional well-being and symptoms of ovarian cancer in women undergoing first-line of chemotherapy: a one-year follow-up

Published:2021-06-02 Issue:12 Volume:29 Page:7421-7430
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Ferracini Amanda Canato^ORCID,Pereira Gabriela,de Souza Cinthia Madeira,dos Santos Thiago Fortes Cabello,Sarian Luís Otávio,Derchain Sophie,Mazzola Priscila Gava

Funder

Coordination of Improvement of Higher Education Personnel

Fundação de Amparo à Pesquisa do Estado de São Paulo

National Council for Scientific and Technological Development – CNPq

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-021-06298-3.pdf

Reference43 articles.

1. Blagden SP, Cook AD, Poole C, Howells L, McNeish IA, Dean A et al (2020) Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncol 21:969–977

2. Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL et al (2016) Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 374:738–748

3. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S et al (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15:396–405

4. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953

5. Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A (2017) Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ 359:j4530

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperthermic intraperitoneal chemotherapy (HIPEC) vs. postoperative intraperitoneal (IP) chemotherapy – Impact on health-related quality of life in primary ovarian cancer patients after cytoreductive surgery;Surgical Oncology Insight;2024-09

2. Systematic Review of the Literature on Multiple Co-occurring Symptoms in Patients Receiving Treatment for Gynecologic Cancers;Seminars in Oncology Nursing;2024-02

3. Symptom Distress and Quality of Life in Women With Newly Diagnosed Ovarian Cancer Undergoing Chemotherapy: A Longitudinal Approach;Clinical Journal of Oncology Nursing;2022-11-18